Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer
16450
post-template-default,single,single-post,postid-16450,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer

Home > Blogs  > Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer

04 Jan Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer

Posted at 07:15h in Blogs by

In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio – 0.28 (p<0.001)]. The corresponding overall survival rate was 94.1% and 85.9% after 12 months, and the overall response was 79.7% and 34.2%. (Ref: Cortés J, et al. N Engl J Med March 24, 2022).

#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6915618089447387136

No Comments

Sorry, the comment form is closed at this time.